Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience

Fangxin Hong, Ph.D., Thomas M Habermann, MD, Leo I. Gordon, MD, Howard S Hochster, MD, Randy D. Gascoyne, MD, Vicki A. Morrison, MD, Richard I Fisher, MD, Nancy L. Bartlett, MD, Patrick J Stiff, MD, Bruce D. Cheson, M.D., Michael Crump, MD FRCPC, Sandra J. Horning, MD, Brad S. Kahl, MD

Blood (2013) 122 (21): 3060.

https://doi.org/10.1182/blood.V122.21.3060.3060

Published: 2013

Journal Articles

A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).

Thomas E. Witzig, MD, Fangxin Hong, Ph.D., Ivana N. Micallef, MD, Randy D. Gascoyne, MD, Ahmet Dogan, MD, PhD, Henry Wagner, Jr., MD, Ranjana H. Advani, MD, Brad S. Kahl, M.D., Sandra J. Horning, M.D.

Blood (2012) 120 (21): 2687.

https://doi.org/10.1182/blood.V120.21.2687.2687

Published: 2012

Journal Articles

Incremental Value in Outcome Prediction with Molecular Signatures in Diffuse Large B-Cell Lymphoma,

Fangxin Hong, Ph.D., Brad S. Kahl, MD, Robert Gray, Ph.D.

Blood (2011) 118 (21): 3687.

https://doi.org/10.1182/blood.V118.21.3687.3687

Published: 2011

Journal Articles

Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CHOP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial.

Ranjana H Advani, MD, Fangxin Hong, Ph.D., Kristen N. Ganjoo, MD, Judith B. Manola, MS, Lode J. Swinnen, MBChB, Thomas M Habermann, MD, Sandra J Horning, MD

Blood (2009) 114 (22): 1671.

https://doi.org/10.1182/blood.V114.22.1671.1671

Published: 2009

Journal Articles

Preliminary Pharmacokinetic (PK) Analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT).

Brad S. Kahl, MD, Michael E. Williams, MD, Fangxin Hong, Ph.D, Randy Gascoyne, MD, Sandra J. Horning, MD

Blood (2007) 110 (11): 3420.

https://doi.org/10.1182/blood.V110.11.3420.3420

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience

A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).

Incremental Value in Outcome Prediction with Molecular Signatures in Diffuse Large B-Cell Lymphoma,

Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CHOP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial.

Preliminary Pharmacokinetic (PK) Analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT).

Email alerts

ASH Publications

American Society of Hematology

Update search

The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience

A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).

Incremental Value in Outcome Prediction with Molecular Signatures in Diffuse Large B-Cell Lymphoma,

Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CHOP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial.

Preliminary Pharmacokinetic (PK) Analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only